GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Anuh Pharma Ltd (BOM:506260) » Definitions » EV-to-EBITDA

Anuh Pharma (BOM:506260) EV-to-EBITDA : 14.40 (As of May. 06, 2024)


View and export this data going back to 1993. Start your Free Trial

What is Anuh Pharma EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Anuh Pharma's enterprise value is ₹11,587 Mil. Anuh Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was ₹805 Mil. Therefore, Anuh Pharma's EV-to-EBITDA for today is 14.40.

The historical rank and industry rank for Anuh Pharma's EV-to-EBITDA or its related term are showing as below:

BOM:506260' s EV-to-EBITDA Range Over the Past 10 Years
Min: 2.97   Med: 11.66   Max: 23.22
Current: 14.4

During the past 13 years, the highest EV-to-EBITDA of Anuh Pharma was 23.22. The lowest was 2.97. And the median was 11.66.

BOM:506260's EV-to-EBITDA is ranked better than
51.14% of 704 companies
in the Drug Manufacturers industry
Industry Median: 14.56 vs BOM:506260: 14.40

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-06), Anuh Pharma's stock price is ₹240.95. Anuh Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was ₹10.840. Therefore, Anuh Pharma's PE Ratio for today is 22.23.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Anuh Pharma EV-to-EBITDA Historical Data

The historical data trend for Anuh Pharma's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anuh Pharma EV-to-EBITDA Chart

Anuh Pharma Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 9.56 9.99 8.22 7.87 6.04

Anuh Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.85 6.04 8.65 8.95 9.13

Competitive Comparison of Anuh Pharma's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Anuh Pharma's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anuh Pharma's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Anuh Pharma's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Anuh Pharma's EV-to-EBITDA falls into.



Anuh Pharma EV-to-EBITDA Calculation

Anuh Pharma's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=11586.749/804.725
=14.40

Anuh Pharma's current Enterprise Value is ₹11,587 Mil.
Anuh Pharma's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹805 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anuh Pharma  (BOM:506260) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Anuh Pharma's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=240.95/10.840
=22.23

Anuh Pharma's share price for today is ₹240.95.
Anuh Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹10.840.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Anuh Pharma EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Anuh Pharma's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Anuh Pharma (BOM:506260) Business Description

Traded in Other Exchanges
N/A
Address
Dr. Annie Besant Road, North Wing, 3-A, Shiv Sagar Estate, Worli, Mumbai, MH, IND, 400 018
Anuh Pharma Ltd is engaged in the business of manufacturing and selling of Bulk drugs and chemicals. Geographically, it derives a majority of revenue from India. Its product categories include macrolides, anti-TB, anti-malarial, anti-bacterial, anti-hypertension, expectorant, quinolones, and others. The company generates revenue from the sale of Branded Prescription drugs, Over-the-Counter (OTC) drugs and Generic Prescription drugs.

Anuh Pharma (BOM:506260) Headlines

No Headlines